Asthma Drugs Global Market Report 2025

Description

Asthma is a chronic respiratory condition characterized by inflammation and constriction of the airways, resulting in difficulty breathing. This condition is triggered by factors such as allergens, leading to airway narrowing and excess mucus production. Asthma drugs play a vital role in managing symptoms associated with asthma.

Asthma can be categorized into allergic and non-allergic types. Allergic asthma involves airway constriction triggered by exposure to allergens, leading to respiratory difficulties. Various triggers for asthma include adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma. Asthma drugs are classified into bronchodilators, monoclonal antibodies, anti-inflammatory drugs, and combination drugs, catering to the needs of asthma and COPD patients.

The asthma drugs market research report is one of a series of new reports from The Business Research Company that provides asthma drugs market statistics, including the asthma drugs industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed asthma drugs market segments, asthma drugs market trends, and opportunities, and any further data you may need to thrive in the asthma drugs industry. This asthma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The asthma drugs market size has grown strongly in recent years. It will grow from $23.96 billion in 2024 to $25.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to environmental factors, increased respiratory disorders, lifestyle changes, healthcare infrastructure development

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $31.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising air pollution levels, growing aging population, increasing healthcare awareness, personalized medicine trends, biopharmaceutical innovations. Major trends in the forecast period include small molecule therapies, home-based asthma care, biomarker-guided therapies, therapeutic advances in severe asthma, collaborations for asthma research.

The rising prevalence of asthma is anticipated to drive growth in the asthma drug market. Asthma is a chronic condition characterized by inflammation and swelling of the airways, which leads to their narrowing and restricts airflow from the nose and mouth to the lungs. Due to the increasing number of asthma cases, there has been a significant rise in the development of new medications to address asthmatic disorders. For example, in April 2024, Asthma + Lung UK, a charity based in England that assists individuals with lung conditions, reported that asthma-related deaths in England rose from 1,146 in 2021 to 1,236 in 2022. This increase highlights a troubling upward trend in fatalities linked to the condition over the past year.

The increasing prevalence of respiratory diseases is set to enhance the asthma drug market. Respiratory diseases are medical conditions that impact the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The rise in respiratory diseases fuels the demand for asthma medications to manage and relieve symptoms associated with these conditions. As respiratory diseases become more common, particularly those like asthma that involve chronic inflammation and airway constriction, the need for effective therapeutic solutions grows. For example, in September 2024, the American Lung Association, a professional organization based in the U.S., reported that over 35 million people in the U.S. were living with a chronic lung condition, such as asthma or COPD, in 2023. Approximately 11.7 million adults, or 4.6% of the population, have been diagnosed with COPD, which encompasses chronic bronchitis and emphysema. Consequently, the rising prevalence of respiratory diseases will propel the asthma drug market forward.

Innovative product development stands as a significant trend gaining traction within the asthma drug market. Major players within this sector are strategically focused on creating novel solutions to maintain their market position. An illustration of this trend is evident in the collaboration between Amgen, a US-based biopharmaceutical company, and AstraZeneca, a UK-based biopharmaceutical company, resulting in the FDA approval of Tezpire, an injectable drug engineered to alleviate asthma symptoms. Tezpire's mechanism of action involves curbing inflammation linked to asthma attacks, exhibiting potential benefits for individuals with severe asthma, including those previously lacking effective treatment options. As the first biologic to consistently reduce asthma-related exacerbations in Phase 2 and 3 clinical trials, the approval of Tezpire promises greater therapeutic advantages, aligning with the escalating instances of asthma cases.

Major companies in the asthma drugs market are prioritizing innovations like fixed-dose combination (FDC) drugs to improve treatment effectiveness and patient adherence. An FDC drug is a medication that combines two or more active ingredients into a single dosage form, such as a tablet, capsule, or inhaler. For example, in June 2022, Glenmark Pharmaceuticals, a pharmaceutical company based in India, launched Indamet, a fixed-dose combination drug aimed at patients with uncontrolled asthma. This innovative treatment merges Indacaterol, a long-acting beta-agonist, with Mometasone Furoate, an inhaled corticosteroid, and is available in various strengths, including Indacaterol 150 mcg with Mometasone at 80 mcg, 160 mcg, and 320 mcg. Designed for once-daily use, Indamet is intended for adults and adolescents aged 12 years and older.

In March 2022, Sandoz, a German pharmaceutical company, successfully acquired Coalesce Product Development Limited for an undisclosed sum. This strategic acquisition aligns with Sandoz's goal of expanding its respiratory division's portfolio and solidifying its global leadership in respiratory products. Through this transaction, Sandoz gains valuable assets and enhanced capabilities in medical and drug-device development, particularly in the respiratory and complex generics markets. The acquisition positions Sandoz to better serve patients with respiratory diseases, including asthma and COPD, by offering affordable and high-quality drug-device combination products, such as inhalers. Coalesce Product Development Limited, based in the UK, is a company specializing in the development of drug delivery devices, boasting a diverse portfolio that includes pressurized metered-dose inhalers, breath-actuated inhalers, pre-metered dry powder inhalers, and more.

Major companies operating in the asthma drugs market include Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd, Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc., Atopix Therapeutics Limited

North America was the largest region in the asthma drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the asthma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma drugs market consists of sales of drugs such as bronchodilators (beta-2 agonists), monoclonal antibodies (omalizumab, mepolizumab), and anti-inflammatory drugs (budesonide, ciclesonide), used for the treatment of asthma in patients of all ages. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asthma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asthma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type Of Asthma: Allergic; Non-Allergic
2) By Asthma Trigger Type: Adult-Onset Asthma; Child-Onset Asthma; Cough-Induced Asthma; Exercise-Induced Asthma; Occupational Asthma; Nocturnal Asthma; Steroid-Resistant Asthma
3) By Therapy: Preventive; Curative
4) By Drug Class: Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs; Combination Drugs
5) By End-User: Asthma Patients; COPD Patients
Subsegments:
1) By Allergic: Inhaled Corticosteroids (ICS); Leukotriene Receptor Antagonists (LTRAs); Monoclonal Antibodies
2) By Non-Allergic: Short-Acting Beta Agonists (SABAs); Long-Acting Beta Agonists (LABAs); Oral Corticosteroids
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24699

1. Executive Summary

2. Asthma Drugs Market Characteristics

3. Asthma Drugs Market Trends And Strategies

4. Asthma Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Asthma Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Asthma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Asthma Drugs Market Growth Rate Analysis
5.4. Global Asthma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Asthma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Asthma Drugs Total Addressable Market (TAM)

6. Asthma Drugs Market Segmentation

6.1. Global Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Allergic
Non-Allergic
6.2. Global Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult-Onset Asthma
Child-Onset Asthma
Cough-Induced Asthma
Exercise-Induced Asthma
Occupational Asthma
Nocturnal Asthma
Steroid-Resistant Asthma
6.3. Global Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preventive
Curative
6.4. Global Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bronchodilators
Monoclonal Antibodies
Anti-Inflammatory Drugs
Combination Drugs
6.5. Global Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asthma Patients
COPD Patients
6.6. Global Asthma Drugs Market, Sub-Segmentation Of Allergic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inhaled Corticosteroids (ICS)
Leukotriene Receptor Antagonists (LTRAs)
Monoclonal Antibodies
6.7. Global Asthma Drugs Market, Sub-Segmentation Of Non-Allergic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Short-Acting Beta Agonists (SABAs)
Long-Acting Beta Agonists (LABAs)
Oral Corticosteroids

7. Asthma Drugs Market Regional And Country Analysis

7.1. Global Asthma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Asthma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Asthma Drugs Market

8.1. Asia-Pacific Asthma Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Asthma Drugs Market

9.1. China Asthma Drugs Market Overview
9.2. China Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Asthma Drugs Market

10.1. India Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Asthma Drugs Market

11.1. Japan Asthma Drugs Market Overview
11.2. Japan Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Asthma Drugs Market

12.1. Australia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Asthma Drugs Market

13.1. Indonesia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Asthma Drugs Market

14.1. South Korea Asthma Drugs Market Overview
14.2. South Korea Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Asthma Drugs Market

15.1. Western Europe Asthma Drugs Market Overview
15.2. Western Europe Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Asthma Drugs Market

16.1. UK Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Asthma Drugs Market

17.1. Germany Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Asthma Drugs Market

18.1. France Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Asthma Drugs Market

19.1. Italy Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Asthma Drugs Market

20.1. Spain Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Asthma Drugs Market

21.1. Eastern Europe Asthma Drugs Market Overview
21.2. Eastern Europe Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Asthma Drugs Market

22.1. Russia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Asthma Drugs Market

23.1. North America Asthma Drugs Market Overview
23.2. North America Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Asthma Drugs Market

24.1. USA Asthma Drugs Market Overview
24.2. USA Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Asthma Drugs Market

25.1. Canada Asthma Drugs Market Overview
25.2. Canada Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Asthma Drugs Market

26.1. South America Asthma Drugs Market Overview
26.2. South America Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Asthma Drugs Market

27.1. Brazil Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Asthma Drugs Market

28.1. Middle East Asthma Drugs Market Overview
28.2. Middle East Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Asthma Drugs Market

29.1. Africa Asthma Drugs Market Overview
29.2. Africa Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Asthma Drugs Market Competitive Landscape And Company Profiles

30.1. Asthma Drugs Market Competitive Landscape
30.2. Asthma Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Asthma Drugs Market Other Major And Innovative Companies

31.1. AstraZeneca PLC.
31.2. GlaxoSmithKline PLC.
31.3. Boehringer Ingelheim International GmbH
31.4. Teva Pharmaceutical Industries Ltd.
31.5. Novartis International AG
31.6. Mylan N.V.
31.7. Cipla Limited
31.8. Chiesi Farmaceutici S.p.A.
31.9. Sun Pharmaceutical Industries Limited
31.10. Hikma Pharmaceuticals
31.11. Mundipharma International Limited
31.12. Lupin Limited
31.13. Glenmark Pharmaceuticals Limited
31.14. Hetero Drugs Limited
31.15. Alembic Pharmaceuticals Limited

32. Global Asthma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Asthma Drugs Market

34. Recent Developments In The Asthma Drugs Market

35. Asthma Drugs Market High Potential Countries, Segments and Strategies

35.1 Asthma Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Asthma Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Asthma Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer